Relay Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M |
| Research and development | $261.4M | $319.1M | $330.0M | $246.4M | $172.7M |
| Operating expenses | $318.1M | $382.5M | $398.5M | $300.7M | $367.7M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$364.7M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M | -$363.9M |
| Balance Sheet | |||||
| Cash and equivalents | $84.0M | $124.3M | $143.7M | $151.8M | $280.1M |
| Current assets | $578.3M | $809.2M | $770.1M | $1.0B | $976.2M |
| Total assets | $621.3M | $871.3M | $844.0M | $1.1B | $1.0B |
| Current liabilities | $25.6M | $50.7M | $30.3M | $63.7M | $24.3M |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M |
| Stockholders' equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$74.4M |
| Depreciation and amortization | $3.6M | $5.5M | $5.3M | $4.1M | $3.9M |
| Stock-based compensation | $62.4M | $94.1M | $86.0M | $56.1M | $48.5M |
| Capital expenditure | $410,000 | $2.0M | $4.1M | $9.1M | $3.5M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$77.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | — | $0 | $0 | $0 | $0 |
Shares outstanding 191.6M · Free float 63.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.